Investment analysts at Nomura started coverage on shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) in a research note issued on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $57.00 price target on the stock. Nomura’s target price points to a potential upside of 174.17% from the company’s previous close.

Several other research analysts also recently weighed in on DCPH. Instinet began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $57.00 target price on the stock. J P Morgan Chase & Co began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday. They issued an “overweight” rating and a $30.00 target price on the stock. Piper Jaffray Companies began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, JMP Securities began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $38.00 target price on the stock. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $43.40.

Shares of Deciphera Pharmaceuticals (DCPH) traded up 3.18% during trading on Monday, hitting $20.79. 282,570 shares of the company traded hands. The stock’s market cap is $663.72 million. The firm has a 50 day moving average price of $21.29 and a 200-day moving average price of $21.29. Deciphera Pharmaceuticals has a one year low of $16.11 and a one year high of $24.50.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/23/nomura-initiates-coverage-on-deciphera-pharmaceuticals-inc-dcph.html.

In related news, major shareholder New Leaf Venture Management Ii purchased 375,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $6,375,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.